AGPS and nervous system disorder: Induction of ADAs has been suggested as an explanation for the lack of clinical efficacy (17); if true, it would make efforts to develop ERT for neurological disorders based on peripheral delivery, or the so-called molecular “Trojan horse” approach, challenging (16).